Inc. The basics Biex develops new products and services to address needs in women's health care, particularly in the area of maternity management. Biex's first product, the SalEst System, determines a pregnant woman's risk of preterm labor and delivery by measuring the levels of the hormone estriol in her saliva. Estriol is an estrogen that plays a key role in the hormonal pathway leading to delivery. Research found that levels of estriol surge two to three weeks before the onset of spontaneous preterm labor and delivery. By measuring levels of the hormone, the SalEst System helps identify women and babies at risk.
Doctors can then intervene and delay birth until the baby has developed further.
A partnership of obstetricians will further advance the integration of the SalEst System into maternity care programs. Calif. VC-6 involvement Technology Funding made its first investment in Biex in July 1993. VC-6 holds 23,076 preferred shares. Technology Funding has a long history of investing in medical technology and health care companies. Preterm birth is widely considered the foremost problem in obstetrical medicine.